These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22347801)

  • 1. Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Ascher-Svanum H; Flynn JA; Tanji Y; Takahashi M
    Clinicoecon Outcomes Res; 2012; 4():13-9. PubMed ID: 22347801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
    Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
    BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.
    Ye W; Ascher-Svanum H; Tanji Y; Flynn JA; Takahashi M; Conley RR
    Neuropsychiatr Dis Treat; 2012; 8():259-66. PubMed ID: 22745559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
    Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
    J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan.
    Ye W; Ascher-Svanum H; Tanji Y; Flynn JA; Takahashi M
    Patient Prefer Adherence; 2011; 5():611-7. PubMed ID: 22259238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
    BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L; Czobor P; Bitter I
    Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
    Fisher MD; Reilly K; Isenberg K; Villa KF
    BMC Psychiatry; 2014 Nov; 14():341. PubMed ID: 25433495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan.
    Qiu H; He Y; Zhang Y; He M; Liu J; Chi R; Si T; Wang H; Dong W
    Aust N Z J Psychiatry; 2018 Dec; 52(12):1202-1212. PubMed ID: 30309245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study.
    Takahashi M; Nakahara N; Fujikoshi S; Iyo M
    Pragmat Obs Res; 2015; 6():39-46. PubMed ID: 27774031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
    Essock SM; Schooler NR; Stroup TS; McEvoy JP; Rojas I; Jackson C; Covell NH;
    Am J Psychiatry; 2011 Jul; 168(7):702-8. PubMed ID: 21536693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy.
    Kristensen D; Hageman I; Bauer J; Jørgensen MB; Correll CU
    J ECT; 2013 Dec; 29(4):271-6. PubMed ID: 23859980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study.
    Zhang SZ; Mu YG; Liu Q; Shi Y; Guo LH; Li LZ; Yang FD; Wang Y; Li T; Mei QY; He HB; Chen ZY; Su ZH; Liu TB; Xie SP; Tan QR; Zhang JB; Zhang CP; Sang H; Mi WF; Zhang HY
    BMC Psychiatry; 2019 Jul; 19(1):216. PubMed ID: 31291931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Pragmat Obs Res; 2012; 3():41-49. PubMed ID: 27774016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.